Details of the Drug

General Information of Drug (ID: DMOF7AT)

Drug Name

Streptozocin

Synonyms

Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Approved	[1]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

265.22

Topological Polar Surface Area (xlogp)

-1.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: The bioavailability of drug is 17-25% [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 15 minutes [3]
Metabolism: The drug is metabolized via the hepatic [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 407.20197 micromolar/kg/day [4]

Chemical Identifiers

Formula: C8H15N3O7
IUPAC Name: 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
Canonical SMILES: CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O
InChI: InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
InChIKey: ZSJLQEPLLKMAKR-GKHCUFPYSA-N

Cross-matching ID

PubChem CID: 29327
ChEBI ID: CHEBI:9288
CAS Number: 18883-66-4
DrugBank ID: DB00428
TTD ID: D0I8RR
ACDINA ID: D01441

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Streptozocin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Streptozocin caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[16]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Streptozocin and Inotersen.	Amyloidosis [5D00]	[17]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Streptozocin and Roflumilast.	Asthma [CA23]	[17]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[18]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
ABT-492	DMJFD2I	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[18]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Streptozocin and Iodipamide.	Cholelithiasis [DC11]	[19]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Streptozocin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[20]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Streptozocin and Denosumab.	Low bone mass disorder [FB83]	[21]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Streptozocin and Clofarabine.	Mature B-cell lymphoma [2A85]	[22]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Streptozocin and Thalidomide.	Multiple myeloma [2A83]	[23]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Streptozocin and Tecfidera.	Multiple sclerosis [8A40]	[24]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Streptozocin and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Streptozocin and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Streptozocin and Ocrelizumab.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Streptozocin and Ozanimod.	Multiple sclerosis [8A40]	[17]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Streptozocin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[27]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[18]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Streptozocin and Canakinumab.	Rheumatoid arthritis [FA20]	[28]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Streptozocin and Rilonacept.	Rheumatoid arthritis [FA20]	[28]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Streptozocin and Golimumab.	Rheumatoid arthritis [FA20]	[29]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Streptozocin and Leflunomide.	Rheumatoid arthritis [FA20]	[20]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Streptozocin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[30]
Doxorubicin	DMVP5YE	Moderate	Additive myelosuppressive effects by the combination of Streptozocin and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[31]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Streptozocin and Azathioprine.	Transplant rejection [NE84]	[16]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[18]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Streptozocin due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[18]
Ganciclovir	DM1MBYQ	Moderate	Increased risk of nephrotoxicity by the combination of Streptozocin and Ganciclovir.	Virus infection [1A24-1D9Z]	[16]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Streptozocin and Valganciclovir.	Virus infection [1A24-1D9Z]	[16]
-----------


⏷ Show the Full List of 35 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium hydroxide	E00234	14798	Alkalizing agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Streptozocin 1gm/vial injectable	1gm/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90.
6	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
7	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
8	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
9	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
10	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
11	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
12	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
13	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
14	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
15	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
16	Cerner Multum, Inc. "Australian Product Information.".
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
19	Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74. [PMID: 20502171]
20	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
21	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
22	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
23	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
24	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
25	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
26	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
27	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
28	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
29	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
30	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
31	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".